eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes
Chen Su, Xumin Li, Shuang Wang, Dan Liu · 2026
Read eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes by Chen Su, Xumin Li, Shuang Wang, Dan Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13573803.txt.
Description
Chen Su, Xumin Li, Shuang Wang, and Dan Liu propose, in a 2026 review, a care frame for kidney disease tied to type 2 diabetes with protein in the urine. Such disease stays high risk in spite of long-used blood pressure drugs that guard the kidney. Two newer drug types guard it in distinct ways: SGLT2 blockers and finerenone. A phase 2 trial found that starting both at once cut urine protein more than each alone in the short term. But that mark does not prove gains in hard outcomes, nor set the best order to start them.
The frame uses two gauges, kidney filter rate and blood potassium, to steer each step. Start, check, pause, ease, and restart are all set out. The stress falls on keeping patients on the drugs, not just on the first script.
Catalog record
| CREATOR | Chen Su, Xumin Li, Shuang Wang, Dan Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |